Published in Cancer Epidemiol on April 26, 2012
Loss of has-miR-337-3p expression is associated with lymph node metastasis of human gastric cancer. J Exp Clin Cancer Res (2013) 1.19
Extracellular microRNAs in urologic malignancies: chances and challenges. Int J Mol Sci (2013) 1.11
A panel of five serum miRNAs as a potential diagnostic tool for early-stage renal cell carcinoma. Sci Rep (2015) 1.09
Comprehensive microRNA analysis identifies miR-24 and miR-125a-5p as plasma biomarkers for rheumatoid arthritis. PLoS One (2013) 1.07
Circulating microRNAs as biomarkers of acute stroke. Int J Mol Sci (2014) 0.92
Oncogenic micro-RNAs and Renal Cell Carcinoma. Front Oncol (2014) 0.92
Serum miR-26a as a diagnostic and prognostic biomarker in cholangiocarcinoma. Oncotarget (2015) 0.89
Combination of MiR-378 and MiR-210 Serum Levels Enables Sensitive Detection of Renal Cell Carcinoma. Int J Mol Sci (2015) 0.89
Noninvasive micromarkers. Clin Chem (2014) 0.86
Integration analysis of microRNA and mRNA expression profiles in human peripheral blood lymphocytes cultured in modeled microgravity. Biomed Res Int (2014) 0.83
MicroRNAs as diagnostic and prognostic biomarkers in colorectal cancer. World J Gastrointest Oncol (2016) 0.82
Differential expression of microRNA501-5p affects the aggressiveness of clear cell renal carcinoma. FEBS Open Bio (2014) 0.81
miR-337 regulates the proliferation and invasion in pancreatic ductal adenocarcinoma by targeting HOXB7. Diagn Pathol (2014) 0.80
Excess of miRNA-378a-5p perturbs mitotic fidelity and correlates with breast cancer tumourigenesis in vivo. Br J Cancer (2014) 0.78
MiRNAs which target CD3 subunits could be potential biomarkers for cancers. PLoS One (2013) 0.78
Clinical utility of microRNA-378 as early diagnostic biomarker of human cancers: a meta-analysis of diagnostic test. Oncotarget (2016) 0.77
Diagnostic and prognostic accuracy of miR-21 in renal cell carcinoma: a systematic review protocol. BMJ Open (2016) 0.77
reSpect: Software for Identification of High and Low Abundance Ion Species in Chimeric Tandem Mass Spectra. J Am Soc Mass Spectrom (2015) 0.76
Identification of aberrant tRNA-halves expression patterns in clear cell renal cell carcinoma. Sci Rep (2016) 0.75
Circulating biomarkers in renal cell carcinoma: the link between microRNAs and extracellular vesicles, where are we now? J Kidney Cancer VHL (2014) 0.75
Identification of circulating microRNA signatures for upper tract urothelial carcinoma detection. Mol Med Rep (2015) 0.75
Expression and functional role of miR-29b in renal cell carcinoma. Int J Clin Exp Pathol (2015) 0.75
Effects of a 28-day dietary co-exposure to melamine and cyanuric acid on the levels of serum microRNAs in male and female Fisher 344 rats. Food Chem Toxicol (2016) 0.75
Identification of microRNA biomarker candidates in urine and plasma from rats with kidney or liver damage. J Appl Toxicol (2016) 0.75
miR-337 can be a key negative regulator in melanoma. Cancer Biol Ther (2017) 0.75
Expression of serum microRNA-378 and its clinical significance in renal cell carcinoma. Genet Mol Biol (2017) 0.75
Recombination: Multiply infected spleen cells in HIV patients. Nature (2002) 4.38
Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med (2010) 4.32
Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol (2013) 2.87
Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res (2006) 2.62
Prognostic significance of venous tumour thrombus consistency in patients with renal cell carcinoma (RCC). BJU Int (2013) 2.10
Comparison of blood group versus HLA-dependent transplantation and its influence on donor kidney survival. Nephrol Dial Transplant (2002) 2.06
Primitive neuroectodermal tumor: rare, highly aggressive differential diagnosis in urologic malignancies. Urology (2006) 1.94
Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol (2011) 1.85
Treatment of penile strangulation caused by constricting devices. Urology (2002) 1.81
MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One (2011) 1.79
The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol Cancer Res (2010) 1.75
Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology (2011) 1.73
Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme. Eur Urol (2012) 1.69
[Aphasia--when the system fails just as much as the language]. Tidsskr Nor Laegeforen (2014) 1.66
Lymph node density affects cancer-specific survival in patients with lymph node-positive urothelial bladder cancer following radical cystectomy. Eur Urol (2011) 1.62
Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology (2006) 1.58
External validation of postoperative nomograms for prediction of all-cause mortality, cancer-specific mortality, and recurrence in patients with urothelial carcinoma of the bladder. Eur Urol (2011) 1.56
A proteome-wide CDK/CRK-specific kinase inhibitor promotes tumor cell death in the absence of cell cycle progression. Chem Biol (2005) 1.47
Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease. Clin Chim Acta (2010) 1.47
Downregulation of several fibulin genes in prostate cancer. Prostate (2007) 1.46
p53 predictive value for pT1-2 N0 disease at radical cystectomy. J Urol (2009) 1.43
Assessing prognosis in metastatic pancreatic cancer by the serum tumor marker CA 19-9: pretreatment levels or kinetics during chemotherapy? Onkologie (2007) 1.42
Circulating microRNAs in serum: novel biomarkers for patients with bladder cancer? World J Urol (2012) 1.39
Treatment of localised renal cell carcinoma. Eur Urol (2011) 1.29
Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. J Cancer Res Clin Oncol (2013) 1.29
Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term followup. J Urol (2007) 1.26
Is there a need to further subclassify pT2 renal cell cancers as implemented by the revised 7th TNM version? Eur Urol (2010) 1.26
Soluble NKG2D ligands: prevalence, release, and functional impact. Front Biosci (2008) 1.24
CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology (2008) 1.24
Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin Cancer Res (2005) 1.22
Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. J Natl Cancer Inst (2009) 1.21
CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer. Prostate (2008) 1.16
Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients. Clin Cancer Res (2012) 1.15
The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res (2010) 1.15
The genomic landscape of meiotic crossovers and gene conversions in Arabidopsis thaliana. Elife (2013) 1.12
Global levels of histone modifications predict prostate cancer recurrence. Prostate (2010) 1.11
Prognostic relevance of global histone H3 lysine 4 (H3K4) methylation in renal cell carcinoma. Int J Cancer (2010) 1.09
Evaluation of reference genes for the analysis of serum miRNA in patients with prostate cancer, bladder cancer and renal cell carcinoma. Int J Urol (2012) 1.07
Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy. Eur Urol (2006) 1.07
Overexpression and amplification of STK15 in human gliomas. Int J Oncol (2004) 1.06
Epigenetic biomarkers in the blood of patients with urological malignancies. Expert Rev Mol Diagn (2015) 1.04
Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy. Tumour Biol (2011) 1.03
Numerical sex chromosome aberrations in juvenile angiofibromas: genetic evidence for an androgen-dependent tumor? Oncol Rep (2003) 1.02
Silencing of the SEC62 gene inhibits migratory and invasive potential of various tumor cells. Int J Cancer (2011) 1.02
Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer. Tumour Biol (2010) 1.02
Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy. Int J Cancer (2013) 1.02
Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy. Tumour Biol (2012) 1.01
Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients. Int J Cancer (2013) 1.00
Noncancerous PTGS2 DNA fragments of apoptotic origin in sera of prostate cancer patients qualify as diagnostic and prognostic indicators. Int J Cancer (2008) 1.00
Association between the number of dissected lymph nodes during pelvic lymphadenectomy and cancer-specific survival in patients with lymph node-negative urothelial carcinoma of the bladder undergoing radical cystectomy. Ann Surg Oncol (2011) 1.00
Sec62 bridges the gap from 3q amplification to molecular cell biology in non-small cell lung cancer. Am J Pathol (2011) 0.99
Factor interaction analysis for chromosome 8 and DNA methylation alterations highlights innate immune response suppression and cytoskeletal changes in prostate cancer. Mol Cancer (2007) 0.98
Clinical studies applying cytokine-induced killer cells for the treatment of renal cell carcinoma. Clin Dev Immunol (2012) 0.98
Incidence and long-term prognosis of papillary compared to clear cell renal cell carcinoma--a multicentre study. Eur J Cancer (2012) 0.97
Global histone H3 lysine 27 (H3K27) methylation levels and their prognostic relevance in renal cell carcinoma. BJU Int (2011) 0.97
Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study. Clin Cancer Res (2009) 0.97
Small intestine submucosa in urethral stricture repair in a consecutive series. Urology (2006) 0.97
Measurements of complement factor H-related protein (BTA-TRAK assay) and nuclear matrix protein (NMP22 assay)--useful diagnostic tools in the diagnosis of urinary bladder cancer? Clin Chem Lab Med (2003) 0.97
The putative serine/threonine kinase gene STK15 on chromosome 20q13.2 is amplified in human gliomas. Oncol Rep (2003) 0.97
Lymph node dissection in renal cell carcinoma. Eur Urol (2011) 0.97
Global histone acetylation levels: prognostic relevance in patients with renal cell carcinoma. Cancer Sci (2010) 0.97